|Bid||87.07 x 1000|
|Ask||87.25 x 1400|
|Day's Range||80.50 - 87.82|
|52 Week Range||3.54 - 189.40|
|Beta (5Y Monthly)||1.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||220.80|
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a Securities and Exchange Commission filing on Wednesday, Novavax (NASDAQ: NVAX) disclosed that the U.K. government had agreed to purchase 60 million doses of NVX-CoV2372, its COVID-19 vaccine candidate. The deal also gives the U.K. the option to make additional orders "from time to time." As part of the agreement, Novavax agreed to create a dedicated supply chain in the U.K. for the production of that country's order.
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.